Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akili, Inc. stock logo
AKLI
Akili
$0.41
+5.1%
$0.29
$0.19
$1.67
$32.13M1.692.86 million shs1.41 million shs
PAVmed Inc. stock logo
PAVM
PAVmed
$2.24
-3.0%
$2.19
$1.60
$9.00
$21.12M0.8366,426 shs101,694 shs
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
$0.40
-2.4%
$0.49
$0.26
$1.14
$14.02M1.5331,827 shs78,736 shs
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$3.65
+21.7%
$3.63
$2.60
$70.00
$20.11M0.05275,538 shs255,123 shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akili, Inc. stock logo
AKLI
Akili
-1.88%+58.27%+40.83%+57.00%-63.99%
PAVmed Inc. stock logo
PAVM
PAVmed
+15.50%+24.86%+13.24%+3.59%-67.15%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
-4.19%-26.43%+3.00%-19.22%-60.38%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
-10.28%+9.06%+1.01%-38.45%-90.03%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akili, Inc. stock logo
AKLI
Akili
3.6624 of 5 stars
3.55.00.00.03.71.71.3
PAVmed Inc. stock logo
PAVM
PAVmed
1.1335 of 5 stars
3.00.00.04.31.10.80.0
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
0.8347 of 5 stars
2.04.00.00.01.01.70.6
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
0.1922 of 5 stars
1.04.00.00.00.70.00.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akili, Inc. stock logo
AKLI
Akili
3.00
Buy$4.00878.47% Upside
PAVmed Inc. stock logo
PAVM
PAVmed
2.00
Hold$21.00837.50% Upside
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/AN/A$3.80850.00% Upside
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
2.00
Hold$3.00-17.81% Downside

Current Analyst Ratings

Latest TTOO, PAVM, SSKN, and AKLI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/29/2024
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$12.00 ➝ $3.00
(Data available from 5/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akili, Inc. stock logo
AKLI
Akili
$1.68M19.15N/AN/A$0.75 per share0.55
PAVmed Inc. stock logo
PAVM
PAVmed
$2.45M8.62N/AN/A($3.35) per share-0.67
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
$33.36M0.42N/AN/A$0.37 per share1.08
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$7.19M2.80N/AN/A($6.91) per share-0.53

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akili, Inc. stock logo
AKLI
Akili
-$59.49M-$0.76N/AN/AN/A-3,545.47%-76.34%-56.48%5/10/2024 (Estimated)
PAVmed Inc. stock logo
PAVM
PAVmed
-$64.18M-$9.33N/AN/A-2,617.25%N/A-85.99%5/21/2024 (Estimated)
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
-$10.83M-$0.31N/AN/AN/A-32.47%-52.50%-17.66%5/20/2024 (Estimated)
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
-$50.08MN/A0.00N/A-696.19%N/A-129.79%5/6/2024 (Confirmed)

Latest TTOO, PAVM, SSKN, and AKLI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024N/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/AN/A  
3/27/2024Q4 2023
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/A-$0.04-$0.04$0.03N/A$8.69 million
3/26/2024Q4 2023
PAVmed Inc. stock logo
PAVM
PAVmed
N/A-$1.57-$1.57-$1.16N/A$1.05 million
2/29/2024Q4 2023
Akili, Inc. stock logo
AKLI
Akili
-$0.26-$0.14+$0.12-$0.14$1.07 million$0.75 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akili, Inc. stock logo
AKLI
Akili
N/AN/AN/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
N/AN/AN/AN/AN/A
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/AN/AN/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akili, Inc. stock logo
AKLI
Akili
0.09
6.02
6.02
PAVmed Inc. stock logo
PAVM
PAVmed
N/A
0.45
0.45
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
1.19
1.28
1.06
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/A
0.45
0.36

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Akili, Inc. stock logo
AKLI
Akili
53.12%
PAVmed Inc. stock logo
PAVM
PAVmed
19.93%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
32.43%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
23.18%

Insider Ownership

CompanyInsider Ownership
Akili, Inc. stock logo
AKLI
Akili
10.10%
PAVmed Inc. stock logo
PAVM
PAVmed
12.60%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
40.43%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
0.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Akili, Inc. stock logo
AKLI
Akili
6878.60 million70.66 millionOptionable
PAVmed Inc. stock logo
PAVM
PAVmed
1079.43 million8.02 millionOptionable
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
9935.06 million20.89 millionNot Optionable
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
1135.51 million5.51 millionOptionable

TTOO, PAVM, SSKN, and AKLI Headlines

SourceHeadline
T2 Biosystems (NASDAQ:TTOO) Price Target Cut to $3.00T2 Biosystems (NASDAQ:TTOO) Price Target Cut to $3.00
americanbankingnews.com - May 1 at 5:32 AM
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
globenewswire.com - April 24 at 9:00 AM
T2 Biosystems (NASDAQ:TTOO) versus Anika Therapeutics (NASDAQ:ANIK) Head to Head ContrastT2 Biosystems (NASDAQ:TTOO) versus Anika Therapeutics (NASDAQ:ANIK) Head to Head Contrast
americanbankingnews.com - April 22 at 1:26 AM
T2 Biosystems converts $15M loan to equity, aims for Nasdaq complianceT2 Biosystems converts $15M loan to equity, aims for Nasdaq compliance
investing.com - April 13 at 6:55 PM
T2 Biosystems, Inc.: T2 Biosystems Shareholders Vote for CRG Debt Conversion into EquityT2 Biosystems, Inc.: T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
finanznachrichten.de - April 12 at 9:52 AM
T2 Biosystems Shareholders Vote for CRG Debt Conversion into EquityT2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
globenewswire.com - April 11 at 4:05 PM
T2 Biosystems, Inc.: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.T2 Biosystems, Inc.: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
finanznachrichten.de - March 28 at 11:09 AM
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
globenewswire.com - March 28 at 9:00 AM
T2 Biosystems, Inc.: T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business UpdatesT2 Biosystems, Inc.: T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
finanznachrichten.de - March 20 at 4:39 PM
T2 Biosystems Targets Commercial Launch Of T2Lyme Panel In Q3 - Quick FactsT2 Biosystems Targets Commercial Launch Of T2Lyme Panel In Q3 - Quick Facts
markets.businessinsider.com - March 20 at 4:39 PM
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business UpdatesT2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
globenewswire.com - March 20 at 7:30 AM
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business UpdatesT2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
globenewswire.com - March 19 at 9:00 AM
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance PanelT2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
globenewswire.com - March 18 at 9:00 AM
TTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq ComplianceTTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq Compliance
investorplace.com - March 12 at 3:16 PM
T2 Biosystems Receives Extension From Nasdaq to Comply With Listing RequirementT2 Biosystems Receives Extension From Nasdaq to Comply With Listing Requirement
360dx.com - March 12 at 10:40 AM
T2 Biosystems, Inc.: T2 Biosystems Receives Extension to Comply with Nasdaq Listing RequirementT2 Biosystems, Inc.: T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
finanznachrichten.de - March 12 at 10:40 AM
T2 Biosystems Receives Extension to Comply with Nasdaq Listing RequirementT2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
globenewswire.com - March 12 at 9:00 AM
T2 Biosystems IncT2 Biosystems Inc
money.usnews.com - February 16 at 10:34 PM
T2 Biosystems (TTOO) share price stays stable post Q4 earningsT2 Biosystems (TTOO) share price stays stable post Q4 earnings
invezz.com - February 16 at 12:34 PM
T2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2023 Earnings Call TranscriptT2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 16 at 12:34 PM
T2 Biosystems (TTOO) share price stays stable post Q4 earningsT2 Biosystems (TTOO) share price stays stable post Q4 earnings
invezz.com - February 16 at 11:09 AM
T2 Biosystems, Inc.: T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and AsiaT2 Biosystems, Inc.: T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
finanznachrichten.de - February 16 at 7:34 AM
Q4 2023 T2 Biosystems Inc Earnings CallQ4 2023 T2 Biosystems Inc Earnings Call
finance.yahoo.com - February 16 at 7:34 AM
T2 Biosystems Preliminary Q4 Revenues Down 69 PercentT2 Biosystems Preliminary Q4 Revenues Down 69 Percent
360dx.com - February 15 at 9:30 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Akili logo

Akili

NASDAQ:AKLI
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.
PAVmed logo

PAVmed

NASDAQ:PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
STRATA Skin Sciences logo

STRATA Skin Sciences

NASDAQ:SSKN
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
T2 Biosystems logo

T2 Biosystems

NASDAQ:TTOO
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.